Synonym
Mdl 28564; Mdl-28564; Mdl28564; Mdl 28,564; Mdl-28,564; Mdl28,564;
IUPAC/Chemical Name
(3S,6S,9S,12S,15S,18S)-3-amino-14-(2-amino-2-oxoethyl)-9-benzyl-18-carbamoyl-6-(hydroxymethyl)-15-isobutyl-12-isopropyl-20-methyl-4,7,10,13-tetraoxo-5,8,11,14,17-pentaazahenicosanoic acid
InChi Key
MSFGGIBCDOMZFX-CJQGIMJOSA-N
InChi Code
InChI=1S/C35H58N8O9/c1-19(2)12-23(16-39-25(31(38)48)13-20(3)4)43(17-28(37)45)35(52)30(21(5)6)42-33(50)26(14-22-10-8-7-9-11-22)40-34(51)27(18-44)41-32(49)24(36)15-29(46)47/h7-11,19-21,23-27,30,39,44H,12-18,36H2,1-6H3,(H2,37,45)(H2,38,48)(H,40,51)(H,41,49)(H,42,50)(H,46,47)/t23-,24-,25-,26-,27-,30-/m0/s1
SMILES Code
O=C(N)CN(C([C@H](C(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@H](CO)NC([C@H](CC(O)=O)N)=O)=O)=O)=O)[C@H](CN[C@H](C(N)=O)CC(C)C)CC(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
734.89
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Buck SH, Harbeson SL, Hassmann CF 3rd, Shatzer SA, Rouissi N, Nantel F, van Giersbergen PL. [Leu9 psi(CH2NH)Leu10]-neurokinin A (4-10) (MDL 28,564) distinguishes tissue tachykinin peptide NK2 receptors. Life Sci. 1990;47(10):PL37-41. PubMed PMID: 2170788.
2: Patacchini R, Astolfi M, Quartara L, Rovero P, Giachetti A, Maggi CA. Further evidence for the existence of NK2 tachykinin receptor subtypes. Br J Pharmacol. 1991 Sep;104(1):91-6. PubMed PMID: 1664768; PubMed Central PMCID: PMC1908267.
3: Maggi CA, Patacchini R, Eglezos A, Quartara L, Giuliani S, Giachetti A. Tachykinin receptors in the guinea-pig renal pelvis: activation by exogenous and endogenous tachykinins. Br J Pharmacol. 1992 Sep;107(1):27-33. PubMed PMID: 1384907; PubMed Central PMCID: PMC1907585.
4: Giuliani S, Patacchini R, Barbanti G, Turini D, Rovero P, Quartara L, Giachetti A, Maggi CA. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors. J Pharmacol Exp Ther. 1993 Nov;267(2):590-5. PubMed PMID: 8246132.
5: Patacchini R, Maggi CA. Effect of newly developed tachykinin agonist and antagonists on the guinea pig isolated gallbladder. J Pharmacol Exp Ther. 1992 Apr;261(1):191-4. PubMed PMID: 1313868.
6: Maggi CA, Eglezos A, Quartara L, Patacchini R, Giachetti A. Heterogeneity of NK-2 tachykinin receptors in hamster and rabbit smooth muscles. Regul Pept. 1992 Jan 23;37(2):85-93. PubMed PMID: 1311459.
7: Astolfi M, Treggiari S, Giachetti A, Meini S, Maggi CA, Manzini S. Characterization of the tachykinin NK2 receptor in the human bronchus: influence of amastatin-sensitive metabolic pathways. Br J Pharmacol. 1994 Feb;111(2):570-4. PubMed PMID: 8004400; PubMed Central PMCID: PMC1909962.
